ELMWOOD PARK, N.J., April 6, 2020 /PRNewswire/ — BioReference Laboratories, Inc., an OPKO Health company (NASDAQ: OPK), today announced that it will continue to prioritize COVID-19 testing for hospital inpatients and critically ill patients around the country. “Our goal is to maintain the current 24 hour turnaround time for these patients,” said Jon R. Cohen, M.D., Executive Chairman of […]
BioReference will offer COVID-19 testing for public drive-through facilities for Miami residents and Larkin Community Hospital ELMWOOD PARK, N.J., March 24, 2020 – BioReference Laboratories, Inc., an OPKO Health company (NASDAQ: OPK), today announced a collaboration with the City of Miami to provide coronavirus disease 2019 (COVID-19) testing. BioReference will provide COVID-19 testing at drive-through locations […]
COVID-19 test will aid healthcare professionals and public health authorities to identify patients infected with COVID-19 ELMWOOD PARK, N.J., March 05, 2020 — BioReference Laboratories, Inc., an OPKO Health company (NASDAQ: OPK), today announced it will offer a test for the novel coronavirus (2019-nCoV), a contagious virus that causes respiratory infection and has shown evidence of human-to-human […]
Elmwood Park, NJ, Nov. 04, 2019 (GLOBE NEWSWIRE) — BioReference Laboratories, Inc., an OPKO Health Company, along with its genetics and genomics laboratory, GeneDx, and women’s health division, GenPath, today announced the presentation of new research from its genetics program at the National Society for Genetic Counselors (NSGC) 38th Annual Conference in Salt Lake City, […]
BioReference Laboratories, Inc., along with its specialty women’s health division, GenPath, today announces the launch of new testing for aerobic vaginitis (AV).
MIAMI, FL NOVEMBER 8, 2018 — BioReference Laboratories, Inc. (BRL), an OPKO Health company and the third largest clinical laboratory in the United States, will remain an in-network provider with Horizon Health Services, Inc. (Horizon), New Jersey’s oldest and largest health insurer. After an extensive evaluation of its laboratory network, BRL will remain a preferred laboratory in the Horizon PPO network. The […]